All In Biotech

Drug Trial Radar · NCT07935356

A Phase 3 Evaluation of Sutacimig in Glanzmann Thrombasthenia

SOLARA: A Phase 3 Study of the Efficacy and Safety of Sutacimig in Participants With Glanzmann Thrombasthenia

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

76

Planned (sponsor's estimate)

Start

Oct 27, 2026

Primary completion

Nov 2029

Study completion Jan 2030

Sponsor

Lead sponsor
Hemab ApSIndustry
Sponsor type
Industry
First posted
Nov 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Glanzmann thrombasthenia (GT) is a serious inherited bleeding disorder. In GT, platelets, the blood cells that normally stick together at the site of an injury to stop bleeding, are unable to properly do so. As a result, bleeding does not stop as it should. Bleeding in GT often starts without warning, can happen frequently, and can be severe. It most commonly affects the nose, mouth and gums, gastrointestinal tract, and skin, and many women and girls with GT experience heavy menstrual bleeding. Over time, bleeding can lead to iron deficiency and anemia. Some bleeding episodes require emergency care, hospitalization, transfusion, or surgery, and some can be life-threatening. Sutacimig is an investigational medicine given as an injection under the skin (subcutaneous injection). It is designed to help platelets work at the site of bleeding despite the underlying defect in GT. It is intended to be given regularly to help prevent bleeding (prophylaxis), rather than only to treat bleeding after it starts. The purpose of this study is to find out whether sutacimig, given as prophylaxis, reduces the number of treated bleeding episodes in people with GT compared with no prophylaxis, and to evaluate its safety and tolerability.

Conditions

  • Thrombasthenia

Interventions

  • SutacimigDrug

    Sutacimig will be administered by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Treated Bleed Rate (ATBR)Time frame: From the first dose through Week 48

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Diego (UC San Diego) Health - Jacobs Medical Center

    La Jolla, California · Not yet recruiting

  • Children's Hospital Los Angeles

    Los Angeles, California · Not yet recruiting

  • University of California Davis (UC Davis) Medical Center

    Sacramento, California · Not yet recruiting

  • University of California San Francisco (UCSF) Medical Center

    San Francisco, California · Not yet recruiting

  • Innovative Hematology - Indiana Hemophilia & Thrombosis Center

    Indianapolis, Indiana · Not yet recruiting

  • M Health Fairview - University of Minnesota Medical Center

    Minneapolis, Minnesota · Not yet recruiting

  • New York-Presbyterian - Weill Cornell Medical Center

    New York, New York · Not yet recruiting

  • Science 37

    Durham, North Carolina · Recruiting

  • Gulf States Hemophilia and Thrombophilia Center - Texas Medical Center

    Houston, Texas · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.